Mutational epitope analysis of Pru av 1 and Api g 1, the major allergens of cherry (Prunus avium) and celery (Apium graveolens):: correlating IgE reactivity with three-dimensional structure
Mutational epitope analysis of Pru av 1 and Api g 1, the major allergens of cherry (Prunus avium) and celery (Apium graveolens):: correlating IgE reactivity with three-dimensional structure
复制标题
DOI:
10.1042/bj20031057
复制
发表时间:
2003-11-15
影响因子:
4.1
通讯作者:
Scheurer, S
中科院分区:
文献类型:
--
作者:
Neudecker, P;Lehmann, K;Scheurer, S
Birch pollinosis is often accompanied by adverse reactions to food due to pollen-allergen specific IgE cross-reacting with homologous food allergens. The tertiary structure of Pru av 1, the major cherry (Prunus avium) allergen, for example, is nearly identical with Bet v 1, the major birch (Betula verrucosa) pollen allergen. In order to define cross-reactive IgE epitopes, we generated and analysed mutants of Pru av 1 and Api g 1.0101, the major celery (Apium graveolens) allergen, by immunoblotting, EAST (enzyme allergosorbent test), CD and NMR spectroscopy. The mutation of Glu(45) to Trp(45) in the P-loop region, a known IgE epitope of Bet v 1, significantly reduced IgE binding to Pru av I in a subgroup of cherry-allergic patients. The backbone conformation of Pru av 1 wild-type is conserved in the three-dimensional structure of Pru av 1 Trp(45), demonstrating that the side chain of Glu(45) is involved in a cross-reactive IgE epitope. Accordingly, for a subgroup of celery-allergic patients, IgE binding to the homologous celery allergen Api g 1.0101 was enhanced by the mutation of Lys(44) to Glu. The almost complete loss of IgE reactivity to the Pru av 1 Pro(112) mutant is due to disruption of its tertiary structure. Neither the mutation Ala(112) nor deletion of the C-terminal residues 155-159 influenced IgE binding to Pru av 1. In conclusion, the structure of the P-loop partially explains the cross-reactivity pattern, and modulation of IgE-binding by site-directed mutagenesis is a promising approach to develop hypo-allergenic variants for patient-tailored specific immunotherapy.